An investigation into the effect of the type IV phosphodiesterase inhibitor rolipram in the modulation of glutamate release from rat prefrontocortical nerve terminals

Synapse. 2006 Jan;59(1):41-50. doi: 10.1002/syn.20212.

Abstract

The present study was conducted to explore the influence of rolipram, a specific inhibitor of the phosphodiesterase type 4 (PDE4) isoform, on glutamate release in the rat prefrontal cortex, using isolated nerve terminal (synaptosome) preparation. In prefrontocortical nerve terminals, rolipram potentiated the Ca(2+)-dependent release of glutamate evoked by 4-aminopyridine (4AP) in a concentration-dependent manner. This potentiation of release was occluded by the activation of PKA by Sp-cAMP or beta-adrenergic receptor agonist and prevented by the inhibition of PKA by Rp-cAMP or KT5720, indicating a PKA-mediated mechanism. The rolipram-mediated potentiation of glutamate release is associated with an increase both in the 4AP-evoked depolarization of the synaptosomal plasma membrane potential and in 4AP-evoked Ca(2+) influx into synaptosomes. Moreover, Ca(2+) ionophore ionomycin-induced glutamate release was also facilitated by rolipram. These results concluded that phosphodiesterase 4 inhibited by rolipram produces an increase in PKA activation, which subsequently enhances the voltage-dependent Ca(2+) influx by increasing terminal excitability as well as the vesicular release machinery to cause an increase in evoked glutamate release from rat prefrontocortical nerve terminals.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • 4-Aminopyridine / pharmacology
  • Animals
  • Calcium / metabolism
  • Calcium Channel Blockers / pharmacology
  • Cyclic AMP / analogs & derivatives
  • Cyclic AMP / pharmacology
  • Dose-Response Relationship, Drug
  • Drug Interactions
  • Glutamic Acid / metabolism*
  • Male
  • Membrane Potentials / drug effects
  • Phosphodiesterase Inhibitors / pharmacology*
  • Potassium Channel Blockers / pharmacology
  • Potassium Chloride / pharmacology
  • Prefrontal Cortex / cytology*
  • Presynaptic Terminals / drug effects*
  • Presynaptic Terminals / metabolism
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Sprague-Dawley
  • Rolipram / pharmacology*
  • Synaptosomes / drug effects
  • Synaptosomes / metabolism
  • Thionucleotides / pharmacology
  • Time Factors
  • omega-Conotoxins / pharmacology

Substances

  • Calcium Channel Blockers
  • Phosphodiesterase Inhibitors
  • Potassium Channel Blockers
  • Protein Kinase Inhibitors
  • Thionucleotides
  • omega-Conotoxins
  • omega-conotoxin-MVIIC
  • adenosine-3',5'-cyclic phosphorothioate
  • Glutamic Acid
  • Potassium Chloride
  • 4-Aminopyridine
  • Cyclic AMP
  • Rolipram
  • Calcium